X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway), developed in partnership with Boehringer in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy and in combination with ezabenlimab (PD-1 antagonist); ongoing expansion Phase 1.
Lead Product(s): OSE-172,Ezabenlimab,Cetuximab
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $1,352.0 million Upfront Cash: $18.4 million
Deal Type: Collaboration May 03, 2022
Details:
The goal of the biomarker analyses from the Phase 1 trial with first-in-class SIRPα inhibitor BI 765063 was to characterize the impact of the product on peripheral blood immune cells (PBMCs), as well as on the tumor microenvironment.
Lead Product(s): OSE-172,Ezabenlimab
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Data from Phase 1 dose escalation indicate that BI 765063 monotherapy or in combination with ezabenlimab is well tolerated and shows promising activity in heavily pre-treated solid tumor patients.
Lead Product(s): OSE-172,Ezabenlimab
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: OSE Immunotherapeutics SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
A BI 765063 dose escalation study in combination with Ezabenlimab (PD-1 antagonist) is ongoing and will help determine the recommended dose for further Phase 2 clinical development in patients with advanced solid tumors.
Lead Product(s): OSE-172,Ezabenlimab
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
BI 765063 (OSE-172) is the first selective antibody antagonist of SIRPα-mediated “Don’t Eat Me” signals. BI 765063 is currently being evaluated in a Phase 1 trial conducted in patients with advanced solid tumors studied in combination with Boehringer Ingelheim’s BI 754091.
Lead Product(s): OSE-172,BI 754091
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
